
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Johnson & Johnson, Novartis and Astellas all took part in the first close of a round for oncology therapy developer 28-7 Therapeutics that now stands at $82.8m.
Milestone, a cardiovascular nasal spray developer that raised more than $167m in VC funding from investors including Novo, secured $82.5m in when it went public.
BGI's gene sequencer spinoff, MGI Tech, has secured $200m in funding from Goldstone Investment, Green Pine Capital and Orient Securities despite a reported $1bn target.
Pfizer, Takeda and Alphabet-backed degenerative disease drug developer Cortexyme priced its initial public offering in the middle of its range to raise $75m.
Corporate joint venture Echo Health Ventures led a $33m funding round that will help fund the home care access platform's expansion in the US.
TigerMed-backed brain monitor developer Neural Analytics boosted its total funding to $66m in a series C round led by existing investor Alpha Edison.
Therachon, which had raised $100m from investors including Pfizer Ventures and Novo, has agreed to be acquired by Pfizer in a deal that could potentially reach $810m.
GV led a $58.5m round for the heart disease drug developer, which came in the wake of a partnership with another Alphabet subsidiary, Verily.
Bennett, Coleman & Co has exited online pharmacy Myra and will receive shares in its new owner, Medlife, as part of the acquisition deal.